Organization | Pancreatic Cancer Research Team

Pancreatic Cancer Research Team Report issue

Academic/Hospital Phase 2

Founded: Seattle WA United States (2003)

Organization Overview

First Clinical Trial

2005

NCT00226005

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2018

Timeline

NOW

Now

Alternative names

Pancreatic Cancer Research Team

Active Ingredients

Drugs in Phase 2 Trials (11)

cisplatin (platinol) (2 trials)

fluorouracil (efudex) (1 trial)

gemcitabine (gemzar) (4 trials)

irinotecan (Camptosar) (1 trial)

leucovorin (1 trial)

oxaliplatin (eloxatin) (1 trial)

paclitaxel (taxol) (4 trials)

pegph20 (1 trial)

pembrolizumab (keytruda) (1 trial)

sitagliptin (januvia) (1 trial)

vatalanib (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adenocarcinoma (Phase 2)

Pancreatic Neoplasms (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 6
# of Trial APIs: 11